Abstract: An antigenic peptide comprises the structure X1-X2-X3-X4-X5-X6-X7-P-X9-X10-X11-X12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X2 is E or S, wherein E and S are as defined above; X3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X5 is P or A as defined above; X6 is V, A or S, wherein V is valine and A and S are as defined above; X7 is D or S as defined above; X9 is D or A as defined above; X10 is N, S or A, wherein N, S and A are as defined above; X11 is E, A or S, wherein E, A and S are as defined above; X12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, that includes a peptide bound to a pharmaceutically acceptable carrier, wherein the peptide is QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), or QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein the IL-23 related disease is one or more of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.

Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHH-WETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.

Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of 7 to 19 amino acid residues consisting of the amino acid sequence (X3)mKDX2QLGX1 (SEQ ID No. 99), wherein X1 is an amino acid residue selected from the group consisting of alanine, asparagine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, serine, threonine, tyrosine and valine, X2 is an amino acid residue selected from the group consisting of alanine, arginine, histidine, isoleucine, leucine, lysine, methionine, threonine, tyrosine and valine. X3 is (X4)nANISX5 (SEQ ID No. 100) or an N-terminal truncated fragment thereof consisting of 1 to 4 amino acid residues, X4 is VVASQLR (SEQ ID No.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: —contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSyn-comprising-aggregates, and —detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).

Abstract: Disclosed is a vaccine, preferably for use in the prevention or treatment of an interleukin 23 (IL-23) related disease, comprising a peptide bound to a pharmaceutically acceptable carrier, wherein said peptide is selected from the group QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322), GHHWETQQIPSLSPSQPWQRL QPEGHHWETQ (SEQ ID No. 98; p8461), TQQIPSLSPSQ (SEQ ID No. 99; p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100; p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101; p9269-C1), and QPEGHHWETQQIPSLSP (SEQ ID No. 102; p9269-C2), especially QPEGHHWETQQIPSLS (SEQ ID No. 103; p8322) and wherein said IL-23 related disease is selected from the group psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, preferably type 1 diabetes, atherosclerosis, inflammatory bowel disease (IBD)/M.

Abstract: The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).

Abstract: The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided. Said antibodies and vaccines are used in therapy, especially in treatment and/or prevention of Type-2 diabetes and cardiovascular disease.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.

Abstract: The present invention relates to a vaccine capable to induce production of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Abstract: The present invention relates to a vaccine comprising at least one peptide consisting of amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1) or a peptide fragment thereof (SEQ ID No. 2-13) coupled or fused to a carrier protein comprising at least one T cell epitope, wherein said peptide fragment comprises at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23) under the provision that the peptide fragment does not consist of amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG (SEQ ID No: 22).

Abstract: The present invention relates to a immunogen comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least two fragments comprise at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID NO:9).

Abstract: Disclosed is a method for detecting aSyn-specific antibodies in a biological sample, comprising the following steps: contacting the sample with aSyn-comprising-aggregates and allowing the aSyn-specific antibodies to bind to the aSsyn-comprising-aggregates, and detecting the aSyn-specific antibodies bound to the aSyn-comprising-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS).